GlassScriptPhysician profile
Ashley Keating
NPI 1811628464
$524.70
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $82.93 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.88 | 2025 | Ozempic, Rybelsus, Wegovy |
| Organon LLC | $82.93 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $51.70 | 2025 | Airsupra |
| Pfizer INC. | $51.51 | 2025 | |
| Insulet Corporation | $37.16 | 2025 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $34.54 | 2025 | Rexulti |
| Lilly USA, LLC | $34.38 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $30.76 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $19.98 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.79 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $17.13 | 2025 | Nexletol |
| Lundbeck LLC | $15.90 | 2025 | Rexulti |
| Viatris Specialty LLC | $15.68 | 2025 | Yupelri |
| Electromed, INC. | $13.84 | 2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.